Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Enliven Therapeutics has raised $460.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Enliven Therapeutics's investors include Cormorant Asset Management, Janus Henderson Investors, OrbiMed, Commodore Capital, 5AM Ventures.
Enliven Therapeutics is headquartered in Boulder, United States.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Enliven Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enliven Therapeutics — Funding & Investors." VCBacked, June 11, 2026, https://www.vcbacked.co/company/enliven-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Enliven Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/enliven-therapeutics
{{cite web |title=Enliven Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/enliven-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated